Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa

Int J Tuberc Lung Dis. 2016 Jul;20(7):985-7. doi: 10.5588/ijtld.15.0905.

Abstract

New drugs offer options for patients with drug-resistant tuberculosis (DR-TB). We describe four individuals with DR-TB in KwaZulu-Natal, South Africa, with prior exposure to clofazimine who would benefit from access to delamanid (DLM). Without DLM, individual options are limited, and there is a risk of resistance amplification and both community and nosocomial spread of DR-TB.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Drug Resistance, Multiple, Bacterial*
  • Drug Therapy, Combination
  • Extensively Drug-Resistant Tuberculosis / diagnosis
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Extensively Drug-Resistant Tuberculosis / microbiology
  • Female
  • Health Services Accessibility
  • Humans
  • Male
  • Nitroimidazoles / therapeutic use*
  • Oxazoles / therapeutic use*
  • South Africa
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Young Adult

Substances

  • Antitubercular Agents
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles